Lv63
2380 积分 2021-02-22 加入
Production of No-Carrier Added Lutetium-177 by Irradiation of Enriched Ytterbium-176
2天前
已完结
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
2天前
已完结
Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development
6天前
已完结
Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside
7天前
已完结
A CDER perspective: Landscape of New Approach Methodologies (NAMs) submitted in drug development programs
18天前
已完结
FDA/CDER/OND Experience With New Approach Methodologies (NAMs)
18天前
已完结
Platform-based opportunities to streamline animal use in support of the 3Rs – recommendations from an antibody-drug conjugate analysis
18天前
已完结
Strategies to reduce the use of non-human primates in development of oncology ADCs with cytotoxic payloads
18天前
已完结
皖公网安备34019202002308
